Status:
COMPLETED
Cohort Study: Modelling Toxicity Processing in Patients Treated by Immunotherapy (MOTIVATE).
Lead Sponsor:
Institut Claudius Regaud
Conditions:
Solid Tumor
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This trial is a multicentric, prospective cohort study of 150 patients aiming to model evolution of toxicity over time in patients with solid tumor and starting first cycle of Immune Checkpoint Inhibi...
Eligibility Criteria
Inclusion
- Age \> or = 18 years old
- Patient with a solid tumor whatever the organ
- Patient receiving an Immune Checkpoint Inhibitor treatment
- Patient starting first cycle of Immune Checkpoint Inhibitor treatment whatever the treatment line
- Patient affiliated to the french social security system
- Patient must provide written informed consent prior to inclusion in the study and any study-specific procedure
Exclusion
- Patient who must receive a treatment other than Immune Checkpoint Inhibitor
- Patient with contraindication to the use of a checkpoint inhibitor (e.g., auto immune disorders requiring an immunosuppressive therapy)
- Pregnant or breastfeeding women
- Any psychological, familial, geographical or sociological condition potentially preventing the medical follow-up and/or study procedures
- Patient protected by law
Key Trial Info
Start Date :
April 20 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 18 2020
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT03447483
Start Date
April 20 2018
End Date
June 18 2020
Last Update
January 12 2021
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
CH ALBI
Albi, France
2
Ch Castres
Castres, France
3
Institut Regional Du Cancer de Montpellier (Icm)
Montpellier, France, 34298
4
Institut Curie
Paris, France, 75005